| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 06/11/2002 | US6403799 Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors |
| 06/11/2002 | US6403792 Sulfonyl isatin compounds and methods of blocking apoptosis therewith |
| 06/11/2002 | US6403791 Treatment of inflammatory diseases or autoimmune diseases in humans or animals |
| 06/11/2002 | US6403775 Erythronolide compounds |
| 06/11/2002 | US6403618 Administering picolinic acid derivatives to chelate with zinc and iron in proteins; antiangiogenic and antineoplastic agent |
| 06/11/2002 | US6403613 Anti-inflammatory agent that reduces levels of cytokines (including tumor necrosis factor) |
| 06/11/2002 | US6403568 For therapy of acquired immunodeficiency syndrome (aids) |
| 06/11/2002 | US6403566 Conformationally locked; antiviral, anticancer, stability to cellular nucleases and strong binding affinity to nucleic acid targets. |
| 06/11/2002 | US6403559 C-kit ligand-based method for expanding peripheral blood cell levels |
| 06/11/2002 | US6403349 Elongation of polyunsaturated fatty acid such as linolenic acid to dihomogamma linolenic acid; nucleotide sequence encodes polypeptide; genetic engineering; animal feeds, nutrients, cosmetics |
| 06/11/2002 | US6403335 Amino acid sequence; promotes survival of mesencephalic cells; nervous system and degenerative disorders; parkinson*s disease; genetic engineering |
| 06/11/2002 | US6403334 gidB from Staphylococcus aureus |
| 06/11/2002 | US6403122 Bioavailability based on a lipolytic indifferent vehicle, an absorption promoter and active n-methylated cyclic undecapeptides or macrolide lactones; self assembly drug delivery system (sadds); cyclosporins |
| 06/11/2002 | US6403102 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 06/11/2002 | US6403099 Conjugates formed from heat shock proteins and oligo-or polysaccharides |
| 06/11/2002 | US6403098 Buffer, sugar, phosphate, recombinant human serum albumin, polysorbate |
| 06/11/2002 | US6403097 Deletion in the glycoprotein ge-gene |
| 06/11/2002 | US6403094 Clostridium perfringens vaccines |
| 06/11/2002 | US6403091 Produced by the hybridoma having atcc accession no. hb 10916. |
| 06/11/2002 | US6403089 Inhibitors of fgl2; bacterial and viral infections, allograft and xenograft rejection, glomerulonephritis, cancer, gastrointestinal diseases and fetal loss; monoclonal and polyclonal antibodies which bind to fgl2 and prevent fibrin |
| 06/11/2002 | US6403082 Administering polynucleotide |
| 06/11/2002 | US6403080 Methods of modulating an immune response to antigen, and cells for use in the method |
| 06/11/2002 | US6403079 Using polypeptide |
| 06/11/2002 | US6402037 Two-photon upconverting dyes and applications |
| 06/11/2002 | CA2240777C Triazole derivatives useful in therapy |
| 06/11/2002 | CA2239705C Quinazoline-4-one ampa antagonists |
| 06/09/2002 | WO2002067993A1 Drug-releasing system of biodegradable polymer type |
| 06/06/2002 | WO2002044718A2 S.aureus protein staau r2, gene encoding it and uses thereof |
| 06/06/2002 | WO2002044406A2 Projection against mycobacterial infections |
| 06/06/2002 | WO2002044395A1 Photochemical internalization for virus-mediated molecule delivery into the cyosol |
| 06/06/2002 | WO2002044384A2 T-cell epitope of the papillomavirus l1 and e7 protein and use thereof in diagnostics and therapy |
| 06/06/2002 | WO2002044383A1 Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them |
| 06/06/2002 | WO2002044364A2 Polypeptides involved in immune response |
| 06/06/2002 | WO2002044334A2 Recombinant rsv virus expression systems and vaccines |
| 06/06/2002 | WO2002044321A2 Rna interference mediating small rna molecules |
| 06/06/2002 | WO2002044320A2 Human elongase genes and uses thereof |
| 06/06/2002 | WO2002044214A1 Methods for the synthesis of a modified hemoglobin solution |
| 06/06/2002 | WO2002044209A2 Cytonkine receptor zcytor19 |
| 06/06/2002 | WO2002044184A2 Dna methyl transferase inhibitors |
| 06/06/2002 | WO2002044183A2 Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors |
| 06/06/2002 | WO2002044178A1 NOVEL β-LACTAM COMPOUNDS AND PROCESS FOR PRODUCING THE SAME |
| 06/06/2002 | WO2002044168A2 Indole-type inhibitors of p38 kinase |
| 06/06/2002 | WO2002044167A1 Process for the crystallization of (r)- or (s)-lansoprazole |
| 06/06/2002 | WO2002044165A1 Quinoline derivatives as nk-3 antagonists |
| 06/06/2002 | WO2002044153A1 4-6-diphenyl pyridine derivatives as antiinflammatory agents |
| 06/06/2002 | WO2002044149A1 Indole and dihydroindole derivatives |
| 06/06/2002 | WO2002044126A2 Bisubstituted carbocyclic cyclophilin binding compounds and theirus |
| 06/06/2002 | WO2002044121A1 Anti-viral compounds |
| 06/06/2002 | WO2002043786A2 Uses for medical devices having a lubricious, nitric oxide-releasing coating for the therapy of vascular disorders |
| 06/06/2002 | WO2002043771A2 Conjugates of glycosylated/galactosylated peptide |
| 06/06/2002 | WO2002043756A2 Method for obtaining antigenic aggregates and the use thereof in formulations |
| 06/06/2002 | WO2002043752A1 Interferon therapeutic effect-potentiating agents |
| 06/06/2002 | WO2002043740A1 Method for producing an immunotropic antiviral preparation |
| 06/06/2002 | WO2002043728A1 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders |
| 06/06/2002 | WO2002043699A2 Preparation of large liposomes by infusion into peg |
| 06/06/2002 | WO2002043664A2 Reducing cellular damage in the human body |
| 06/06/2002 | WO2002043660A2 Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
| 06/06/2002 | WO2002043651A2 Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease |
| 06/06/2002 | WO2002043649A2 Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof |
| 06/06/2002 | WO2002043648A2 Compounds active at the glucocorticoid receptor ii |
| 06/06/2002 | WO2002043570A2 METHODS FOR THE PREVENTION AND TREATMENT OF CANCER USING ANTI-C3B(i) ANTIBODIES |
| 06/06/2002 | WO2002043567A2 A method of treating cancer |
| 06/06/2002 | WO2002028426A8 Split enveloped virus preparation |
| 06/06/2002 | WO2002024223A3 Prevention and treatment of streptococcal and staphylococcal infection |
| 06/06/2002 | WO2002020555A3 Hiv peptides from tat, rev and wef conserved regions and their application as e.g.vaccine components |
| 06/06/2002 | WO2002020483A8 Piperidine derivatives for use 2,3-oxidosqualene-lanosterol cyclase inhibitors |
| 06/06/2002 | WO2002017900A9 Modulators of us28 (chemokines) for treating cytomegalovirus infections |
| 06/06/2002 | WO2002016440A3 Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of haemophilus influenzae infections |
| 06/06/2002 | WO2002015866A3 USE OF CYCLIC 2,4-DIPHOSPHOGLYCERATES (cDGP) AND/OR DERIVATIVES THEREOF IN COSMETIC AND DERMATOLOGICAL FORMULATIONS |
| 06/06/2002 | WO2002014448A3 Adhesive blends comprising hydrophilic and hydrophobic pressure sensitive adhesives |
| 06/06/2002 | WO2002012242A3 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 06/06/2002 | WO2002011676A3 Method of using diketopiperazines and composition containing them |
| 06/06/2002 | WO2002010764A3 SPECIFIC BINDING AGENTS FOR KSHV vIL-6 THAT NEUTRALIZE A BIOLOGICAL ACTIVITY |
| 06/06/2002 | WO2002007683B1 Antimicotic nail varnish composition |
| 06/06/2002 | WO2002004406A3 9-substituted minocycline compounds |
| 06/06/2002 | WO2002002606A3 Immunisation against chlamydia pneumoniae |
| 06/06/2002 | WO2001097791A3 Use of c4-c10 acids for preventing gram-negative bacterial infections |
| 06/06/2002 | WO2001090334A3 Drug metabolizing enzymes |
| 06/06/2002 | WO2001090129A3 Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds |
| 06/06/2002 | WO2001090068A3 Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use a modulators of protein kinases |
| 06/06/2002 | WO2001087849A3 Modulators of tnf- alpha signaling |
| 06/06/2002 | WO2001080840A3 Cytotoxic agents comprising single-stranded and/or looped dna |
| 06/06/2002 | WO2001079442A3 Albumin fusion proteins |
| 06/06/2002 | WO2001074768A3 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| 06/06/2002 | WO2001074128A3 A novel polypeptide, microtubulin 11 and the polynucleotide encoding the polypeptide |
| 06/06/2002 | WO2001072323A3 Use of insulin for the treatment of cartilagenous disorders |
| 06/06/2002 | WO2001068643A3 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines |
| 06/06/2002 | WO2001064907A3 Lipid metabolism enzymes |
| 06/06/2002 | WO2001064884A3 G12l, a gene associated with the thermal response |
| 06/06/2002 | WO2001048209B1 Genes identified as required for proliferation of e. coli |
| 06/06/2002 | WO2001045727A3 Stabilized veterinary compositions comprising more than one antiviral agent |
| 06/06/2002 | WO2001023604A9 Highly conserved genes and their use to generate probes and primers for detection of microorganisms |
| 06/06/2002 | WO2000024782A3 Modified peptides, comprising an fc domain, as therapeutic agents |
| 06/06/2002 | WO2000022430A3 Neisseria genomic sequences and methods of their use |
| 06/06/2002 | US20020068753 2,3-oxidosqualene-lanosterol cyclase inhibitors |
| 06/06/2002 | US20020068738 Cannabichromene derivative is exposed to the virus, a host cell, or an infected cell under conditions sufficient to inhibit the replication or proliferation of the virus, especially HIV. |
| 06/06/2002 | US20020068720 Containing s cyclodextrin compound in a concentration sufficient to maintain the drug in solution at such a drug concentration. |
| 06/06/2002 | US20020068714 Screening for agents that modulate tolerance to an immunogen; delivering a nucleic acid that directs expression of the immunogen to the liver of an animal, resulting in sustained expression of the immunogen in the liver. |
| 06/06/2002 | US20020068702 Containing eleven amino acid residues |
| 06/06/2002 | US20020068319 32 human secreted proteins |